Enanta Pharmaceuticals Inc (ENTA)
12.49
+0.49
(+4.08%)
USD |
NASDAQ |
May 31, 16:00
12.43
-0.06
(-0.48%)
After-Hours: 20:00
Enanta Pharmaceuticals Cash from Financing (Quarterly): -6.414M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -6.414M |
| December 31, 2023 | -7.35M |
| September 30, 2023 | -0.023M |
| June 30, 2023 | 199.88M |
| March 31, 2023 | -2.027M |
| December 31, 2022 | 0.301M |
| September 30, 2022 | 2.93M |
| June 30, 2022 | 4.12M |
| March 31, 2022 | 3.351M |
| December 31, 2021 | 9.632M |
| September 30, 2021 | 0.943M |
| June 30, 2021 | 0.686M |
| March 31, 2021 | 1.152M |
| December 31, 2020 | 0.299M |
| September 30, 2020 | 0.233M |
| June 30, 2020 | 3.226M |
| March 31, 2020 | 4.358M |
| December 31, 2019 | 1.166M |
| September 30, 2019 | 0.687M |
| June 30, 2019 | 0.49M |
| March 31, 2019 | 0.257M |
| December 31, 2018 | 1.14M |
| September 30, 2018 | 1.033M |
| June 30, 2018 | 2.965M |
| March 31, 2018 | -0.006M |
| Date | Value |
|---|---|
| December 31, 2017 | 0.417M |
| September 30, 2017 | 1.007M |
| June 30, 2017 | 0.19M |
| March 31, 2017 | -0.211M |
| December 31, 2016 | 0.031M |
| September 30, 2016 | 0.061M |
| June 30, 2016 | 1.968M |
| March 31, 2016 | 0.53M |
| December 31, 2015 | 0.146M |
| September 30, 2015 | 0.159M |
| June 30, 2015 | 0.122M |
| March 31, 2015 | 0.245M |
| December 31, 2014 | 2.014M |
| September 30, 2014 | 0.044M |
| June 30, 2014 | 0.474M |
| March 31, 2014 | 0.557M |
| December 31, 2013 | 0.089M |
| September 30, 2013 | 0.122M |
| June 30, 2013 | -1.445M |
| March 31, 2013 | 59.55M |
| December 31, 2012 | -1.32M |
| September 30, 2012 | -0.991M |
| June 30, 2012 | -0.025M |
| March 31, 2012 | 0.056M |
| December 31, 2011 | 0.051M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-7.35M
Minimum
Dec 2023
199.88M
Maximum
Jun 2023
10.88M
Average
0.815M
Median
Cash from Financing (Quarterly) Benchmarks
| Madrigal Pharmaceuticals Inc | 573.71M |
| Galectin Therapeutics Inc | 10.00M |
| Viking Therapeutics Inc | 606.04M |
| Akero Therapeutics Inc | 366.94M |
| 89bio Inc | 21.03M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -28.60M |
| Cash from Investing (Quarterly) | 58.62M |
| Free Cash Flow | -113.29M |
| Free Cash Flow Per Share (Quarterly) | -1.43 |
| Free Cash Flow to Equity (Quarterly) | -30.27M |
| Free Cash Flow to Firm (Quarterly) | -30.27M |
| Free Cash Flow Yield | -43.01% |